Abstract
Neurosteroids play essential roles in the control of central nervous system functions during physiological and pathological conditions. Increasing evidences show gender differences in the pathogenesis and clinical manifestations of several neurodevelopmental conditions, including Autism Spectrum Disorders (ASD), possibly due to the action of sex hormones during critical periods of brain development. Furthermore, it is known that neuroactive steroids contribute to neuroprotection, spinogenesis, synaptogenesis, as well as to modulation of neuronal excitability via their interaction with GABA receptors. Dysfunctions of GABAergic signaling early in development lead to a severe excitation-inhibition unbalance in neuronal circuits, which may contribute to the pathophysiology of autism.
In this review, we summarize recent data concerning the functional role of neurosteroids and their relationship with the GABAergic system, focusing on GABA-mediated neurotrasmission alterations characterizing some neurodevelopmental disorders.
Keywords: Brain sexual dimorphism, neurosteroids, neurodevelopmental disorders, GABA receptors, autism, synaptic plasticity, estrogen, androgen.
Current Pharmaceutical Design
Title:Focusing on the Interactions between the GABAergic System and Neurosteroids in Neurodevelopmental Disorders
Volume: 19 Issue: 36
Author(s): Francesca Fanelli, Ramona Marino and Flavio Keller
Affiliation:
Keywords: Brain sexual dimorphism, neurosteroids, neurodevelopmental disorders, GABA receptors, autism, synaptic plasticity, estrogen, androgen.
Abstract: Neurosteroids play essential roles in the control of central nervous system functions during physiological and pathological conditions. Increasing evidences show gender differences in the pathogenesis and clinical manifestations of several neurodevelopmental conditions, including Autism Spectrum Disorders (ASD), possibly due to the action of sex hormones during critical periods of brain development. Furthermore, it is known that neuroactive steroids contribute to neuroprotection, spinogenesis, synaptogenesis, as well as to modulation of neuronal excitability via their interaction with GABA receptors. Dysfunctions of GABAergic signaling early in development lead to a severe excitation-inhibition unbalance in neuronal circuits, which may contribute to the pathophysiology of autism.
In this review, we summarize recent data concerning the functional role of neurosteroids and their relationship with the GABAergic system, focusing on GABA-mediated neurotrasmission alterations characterizing some neurodevelopmental disorders.
Export Options
About this article
Cite this article as:
Fanelli Francesca, Marino Ramona and Keller Flavio, Focusing on the Interactions between the GABAergic System and Neurosteroids in Neurodevelopmental Disorders, Current Pharmaceutical Design 2013; 19 (36) . https://dx.doi.org/10.2174/1381612811319360009
DOI https://dx.doi.org/10.2174/1381612811319360009 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Early Detection of Epileptic Seizures in Sparse Domains
Neuroscience and Biomedical Engineering (Discontinued) Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry Comparison of Valvulopathy Risk with Lorcaserin and Phenterminetopiramate for Weight Loss
Current Drug Therapy Editorial [Hot Topic: Regulation of Glutamate Synthesis Via Inhibition of Glutamate Carboxypeptidase II (GCPII): An Effective Method to Treat Central and Peripheral Nervous System Disorders (Guest Editors: Guido Cavaletti and Barbara Slusher)]
Current Medicinal Chemistry Update on Pharmacological Treatment of Progressive Myoclonus Epilepsies
Current Pharmaceutical Design Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Voltage-Gated Sodium Channels as Therapeutic Targets for Treatment of Painful Diabetic Neuropathy
Mini-Reviews in Medicinal Chemistry The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy
Current Molecular Imaging (Discontinued) Role of Pharmacogenomics in Antiepileptic Drug Therapy: Current Status and Future Perspectives
Current Pharmaceutical Design Neurogenic Drugs and Compounds
Recent Patents on CNS Drug Discovery (Discontinued) Nanotechnology and Drug Delivery: Getting There is Only Half of the Challenge! (Commentary)
CNS & Neurological Disorders - Drug Targets Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications
Current Drug Metabolism Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets Lithium in Psychiatry-The Benefits and Risks Associated with the Lithium Salts Treatment in Affective Disorders
Current Psychopharmacology Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology AMPK As A Target in Rare Diseases
Current Drug Targets Potential for Discovery of Neuroprotective Factors in Serum and Tissue from Hibernating Species
Mini-Reviews in Medicinal Chemistry Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors
Current Gene Therapy